Key Highlights

  • Saturday, October 24, 2026 data showed a 58% reduction in death risk for Imdelltra plus Imfinzi versus Imfinzi alone in DeLLphi-305.
  • Median overall survival reached 21.1 months compared with 12.7 months, while 12-month survival was 79% versus 53%.
  • AstraZeneca supplied Imfinzi and partly funded the 563-patient Phase III trial, which Amgen sponsored and presented at ESMO 2026 in Madrid.
  • Grade 3 to 4 treatment-related events occurred in 20.9% of combination patients and 10.8% of controls, with no treatment-related deaths reported.

What Did the DeLLphi-305 Survival Results Establish?

Amgen (NASDAQ:AMGN) presented DeLLphi-305 during the ESMO 2026 Presidential Symposium in Madrid on Saturday, October 24, 2026, with publication in a medical journal. The Phase III study enrolled 563 patients whose extensive-stage small-cell lung cancer had not advanced after first-line Imfinzi, platinum chemotherapy and etoposide. Maintenance was randomised between Imdelltra plus Imfinzi and Imfinzi alone.

For overall survival, investigators calculated a 0.42 hazard ratio and a p-value under 0.001, equivalent to mortality risk falling 58%. The median lengthened by 8.4 months on simple arithmetic, moving from 12.7 to 21.1 months. Time without progression measured 7.4 months for the combination and 1.9 for control; confirmed responses were 26.4% and 4.1%, respectively. Patients whose cancer had reached the liver or brain also benefited.

How Could First-Line Maintenance Broaden Imdelltra's Commercial Reach?

Imdelltra, also called tarlatamab, is a bispecific T-cell engager that connects immune T cells with cancer cells expressing DLL3. Maintenance treatment is given after initial therapy succeeds, with the aim of delaying relapse. Moving from later use into that earlier position can increase both eligible patient numbers and treatment duration, the main drivers of medicine revenue.

The 12-month survival comparison of 79% with the combination and 53% with Imfinzi alone indicates the clinical magnitude. AstraZeneca (NASDAQ:AZN) also has an interest because its therapy stays at the centre of the regimen. That company supplied Imfinzi and helped fund the trial, while Amgen served as sponsor.

Could Higher Toxicity and DLL3 Competition Slow Adoption?

Grade 3 to 4 treatment-related side effects rose to 20.9% from 10.8%. T-cell engagers require monitoring, which may limit use beyond large oncology centres, even though investigators reported no deaths caused by treatment and a low discontinuation rate. The companies also provided no submission schedule for the combination.

Competition is developing around DLL3. Zymeworks (NASDAQ:ZYME) licensed ZW209 to Roche on Friday, October 23, 2026. A competing asset remains earlier than Imdelltra but shows that a Phase III lead does not eliminate future rivals. Regulatory timing, safety in wider practice and commercial execution all remain unresolved.

What to Watch Next: Will October 27 and 28 Clarify the DLL3 Race?

At 8:30 a.m. ET on Tuesday, October 27, 2026, Zymeworks discusses its competing programme. Monetary policy is announced the following day, Wednesday, October 28. The direct corporate milestone would be an Amgen statement defining both a regulatory-submission plan and its timing.

A 58% death-risk reduction and an 8.4-month median-survival improvement create a case for first-line maintenance. The higher adverse-event rate and missing regulatory schedule qualify that conclusion. Clinical results do not assure approval or future revenue. This analysis does not provide investment advice.

Moving a medicine earlier changes the treatment population as well as the evidence required from clinicians. Patients in maintenance have already benefited from initial therapy, so the incremental survival gain must be weighed against additional monitoring and toxicity. DeLLphi-305 provides comparative numbers for that discussion, while the missing submission timetable prevents a firm commercial start date. The competitor call may illuminate the target class, but only Amgen can disclose its own regulatory plan.